An Epilepsy Drug Was Linked to Fewer Migraine Aura Days

A woman holding her temples while experiencing a migraine headache.
Pixabay / fairpharma

Migraine aura can cause visual disturbances, numbness, and problems with speech and language. There is still no established preventive treatment aimed specifically at migraine aura.

Researchers at Lund University in Sweden examined whether lamotrigine, a drug used to treat epilepsy and bipolar disorder, could help patients whose migraine aura caused particularly severe problems.

Before treatment with lamotrigine, patients had an average of 6.9 aura days per month. During treatment, that fell to an average of 1.4 days per month.

Overall, 85.2 percent of patients experienced at least a 50 percent reduction in aura days. The average reduction was nearly 80 percent.

A large change, but no control group

The change was substantial, but the study design cannot determine how much of it was caused by the drug itself.

There was no placebo group or other control group, and patients were not randomly assigned to treatment. The study looked back at patients whom doctors had already decided to treat with lamotrigine.

Migraine symptoms can also fluctuate over time. Without a control group, it is difficult to separate the drug’s possible effect from natural changes in symptoms or other changes occurring at the same time.

Lamotrigine is not approved for the treatment of migraine. It is commonly used to treat epilepsy and bipolar disorder.

Why might lamotrigine affect migraine aura?

The researchers were interested in the drug because of a possible mechanism involved in migraine aura. Aura is thought to involve cortical spreading depolarization, a wave of altered electrical activity that moves across neurons and supporting cells in the cerebral cortex.

Lamotrigine affects electrical signaling in nerve cells and, among other effects, reduces the release of glutamate.

Blister packs containing medication tablets.
Pixabay / D G

Previous studies of lamotrigine have produced mixed results. The Lund study, however, focused specifically on patients for whom aura was the dominant or particularly burdensome part of their migraine.

Adverse effects were reported by 29 patients, or 35.8 percent of participants. Skin-related symptoms were the most common. Five patients stopped treatment because of adverse effects. One patient discontinued treatment after developing Stevens–Johnson syndrome.

A controlled trial is the next step

The researchers do not consider the findings definitive evidence that lamotrigine is effective for migraine aura. They do, however, provide a strong enough signal to justify a controlled clinical trial.

According to Lund University, researchers are preparing a national randomized, double-blind, placebo-controlled trial. It will test whether lamotrigine reduces migraine aura more effectively than placebo.

The medical-record study included 81 patients treated at a neurology clinic in Lund between 2014 and 2022.

The study was published on July 29, 2026, in Frontiers in Neurology. Lund University published a research news article about the study on September 24, 2026.

RESEARCH REFERENCE

Reference: “Lamotrigine prophylaxis is associated with reduced aura frequency in patients with burdensome migraine aura: a retrospective observational study” by Sena Uzun, Ulf Frejvall, Hulya Karatas, Per Petersson, Gürdal Sahin, 29 July 0026, Frontiers in Neurology.
DOI: 0.3389/fneur.2026.1863747

Want to see more from HUMANUMi in Google?

More on This Topic

Latest News

More Latest News